In Vitro Comparison Of Generic And Branded Formulations Of Ceftazidime Using Standard Strain Of Pseudomonas
In Vitro Comparison Of Generic And Branded Formulations Of Ceftazidime Using Standard Strain Of Pseudomonas
Keywords:
Ceftazidime, Pseudomonas, Generic drug, Brand drug,MIC,MBCAbstract
Background& Objective: Use of generic medicines has been increasing in recent years as a cost saving
measure in health care provision. But, there is an uncertainty about whether the quality of a generic medicine is
equal to, greater than or less than its equivalent brand-name drug. Its quality must be evaluated in vitro and in vivo
in order to confirm their suitability for therapeutic use. Here, we have done in vitro comparison of generic and brand
formulation of ceftazidime against pseudomonas standard strain (ATCC 27853). Methodology: One generic and three
brands of ceftazidime were selected for in vitro comparison. Microbiological assays were used to establish the
Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) against pseudomonas
standard strain (ATCC 27853) according CLSI (Clinical Laboratory Standard Institutes) guidelines. Results: The MIC
values of the ceftazidime samples evaluated (Brand and generics) were the same for pseudomonas standard strain
tested, indicating that all products behaved similarly. The MBC values were very similar for all samples. Overall,
therefore, the results showed no significant differences among samples. Conclusion: Reference method MIC and
MBC testing of ceftazidime against pseudomonas has demonstrated no significant difference in in vitro activity
between generic and brand products. [Tank N NJIRM2016; 7(2):31-36]
References
Lack of pharmacokinetic bioequivalence between
generic and branded amoxicillin formulations - A
post-marketing clinical study on healthy
volunteers. Br J Clin Pharmacol. 2009; 68: 34–42.
2. Jan Aushadhi: An Initiative of Government of
India/Generic Medicine Campaign Improving
Access to Medicines [Internet]. [cited 2015 July
15]. Available from:
http://janaushadhi.gov.in/about_jan_aushadhi.ht
ml.
3. CLSI document M07-A 10. Methods for Dilution
Antimicrobial Susceptibility Tests for Bacteria That
Grow Aerobically; Approved standard-10th Ed.
Wayne, PA: Clinical and Laboratory Standard
Institute; 2015.
4. W Lowman, R Stewart, N Aithma, Z Mjindi, J
Loakes. A comparative in vitro microbiological
evaluation of generic meropenem compounds
against the innovator compound. South Afr J
Epidemiol Infect. 2011; 26: 73-77.
5. Lowman W, Aithma N, Coetzee J, Dusè A, Mer M.
Comparative MIC evaluation of a generic
ceftriaxone by broth microdilution on clinically
relevant isolates from an academic hospital
complex in South Africa. S Afr Med J. 2012; 102:
102-103.
6. Tripathi KD. Essentials of Medical Pharmacology
7thEd. New Delhi: Jaypee Brothers Medical
Publishers (P) Ltd; 2013, pp 696-97 & 725.
7. Gallelli L, Palleria C, Vuono A, et al. Safety and
efficacy of generic drugs with respect to brand
formulation. J Pharmacol Pharmacother. 2013; 4:
110–114.
8. Gavura S. Generic Drugs: Are they Equivalent?
[Internet]. 2012 [cited 2015 July 15] Available
from:
https://www.sciencebasedmedicine.org/genericdrugs-
are-they-equivalent/ .
9. What are Generic Drugs? - A Fact Sheet [Internet].
2012 [cited 2015 July 15]. Available from:
http://www.pharmaceutical-drugmanufacturers.
com/articles/generic-drugs.html
10. Pais KP, Panchmal GS, Shenoy R, Tellis R, et al.
Comparison of Medicine Quality of the Generic
Formulation of Amoxicillin Provided by the
Government of Karnataka with Marketed Brands -
A Public Health Perspective. Int. J. Pharm. Sci. Rev.
Res. 2013; 23: 37-42.
11. Tidy C, Knott L. Patient information- pseudomonas
[Internet]. 2013 [cited 2015 July 15]. Available
from: http://patient.info/doctor/pseudomonas
12. Fortaz- Food and Drug Administration [Internet].
2013 [cited 2015 July 15]. Available
from:http://www.accessdata.fda.gov/drugsatfda_
docs/label/2004/50578slr046,50634slr016_fortaz_
lbl.pdf
13. Silva E, Diaz JA, Arias MJ, Hernandez AP, Torre A.
Comparative in vitro study of the antimicrobial
activities of different commercial antibiotic
products for intravenous administration. BMC
Clinical Pharmacology. 2010; 10: 3
14. Diaz JA, Silva E, Arias MJ, Garzon M. Comparative
in vitro study of the antimicrobial activities of
different commercial antibiotic products of
vancomycin. BMC Clinical Pharmacology. 2011; 11:
9.
15. Garyj M, Amya W, Helios S, Ronaldn J. Expanded
studies of piperacillin/Tazobactam formulation:
variation among branded product lots and
assessment of 46 generic lots. Diagnostic
Microbiology and Infectious Disease. 2009; 65:
319-322.
16. Zuluaga AF, Agudelo M, Rodriguez CA, Vesga O.
Application of microbiological assay to determine
pharmaceutical equivalence of generic intravenous
antibiotics. BMC Clinical Pharmacology. 2009; 9: 1.
17. Andrews JM. Antimicrobial Susceptibility testing:
BSAC working report. J Antimicrob Chemother.
2001; 48: 5-16
